Skip to content
OpenCapital
Get started

Cullinan Therapeutics, Inc. CGEM Q4 2024 Annual earnings

Reported February 27, 2025 · Before market open

EPS-$0.73Beat by $0.02
EPS estimate-$0.75

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$3.7M
EPS estimate-$0.80

Financials

Q4 2024

Income statement

See full
Operating income-$55.0M-21.0%
Net income-$47.6M-100%

Balance sheet

See full
Cash & equivalents$83.0M-15.7%
Total debt$2.2M-40.1%
Total equity$590.3M+30.1%
Total assets$621.8M+28.4%

Cash flow

See full
Operating cash flow-$36.6M-102%
CapEx-—
Free cash flow-$36.6M-102%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$709.21M+62.6%
Enterprise value$628.36M+84.1%

Returns & leverage

See full
Return on equity-32.1%+1.2pp
Debt / equity0×0.0×
Current ratio13.5×-3.5×

Versus estimates

Diluted EPS

Q1 2026-$0.75Beat by $0.09Q4 2025-$0.77Beat by $0.03Q3 2025-$0.77Beat by $0.18Q2 2025-$1.07Miss by $0.24Q1 2025-$0.74Beat by $0.04
Q4 2024-$0.73Beat by $0.02

Ask the moment Cullinan Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cullinan Therapeutics, Inc. report Q4 2024 earnings?
Cullinan Therapeutics, Inc. (CGEM) reported Q4 2024 earnings on February 27, 2025 before market open.
What were Cullinan Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Cullinan Therapeutics, Inc. reported eps of $-0.73 for Q4 2024.
Did Cullinan Therapeutics, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.75 by $0.02.
Where can I find Cullinan Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-028346) directly on SEC EDGAR. The filing index links above go to sec.gov.